Slow Bull
The market, slowly. SATURDAY, 26 SEPTEMBER 2026

Context Therapeutics Inc.

CNTX Nasdaq SEC CIK 1842952
Follow Context Therapeutics Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$14.6M −64.9% vs same quarter last year
EPS, diluted −$0.15 −66.7% vs same quarter last year
Operating cash flow −$7M −20.3% vs same quarter last year
Operating income −$15M −53.4% vs same quarter last year
Net income by quarter
−$17.5M
−$3.3M
−$4.6M
−$8.8M
−$9.7M
−$13M
−$8.7M
−$14.6M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$40M−$20M$0$20MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$36.1M
FY24−$26.7M
FY23−$24M
FY22−$14.8M
FY21−$10.5M
FY20$6.6M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$26.4M
FY24−$14.6M
FY23−$21M
FY22−$13.6M
FY21−$8.8M
FY20-
FY19-

News

No stories filed under Context Therapeutics yet - coverage appears here as the news feed clusters it.